AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca RSS Channel

Display # 
Title Published Date
AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US 23 November 2015
AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma 06 November 2015
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations 22 October 2015
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis 01 October 2015
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline 11 September 2015
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester 08 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack 04 September 2015
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab 01 September 2015
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial 24 August 2015
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments 07 August 2015

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]